Evidence map›Paper›PMID 39064796›Full record

ReviewNutrients2024

Saffron as a Promising Therapy for Inflammatory Bowel Disease.

Mudasir Rashid, Rumaisa Rashid, Sabtain Saroya, Mrinalini Deverapalli, Hassan Brim, Hassan Ashktorab

Abstract readReview
In one paragraph

Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mudasir RashidDepartment of Medicine and Cancer Center, Howard University College of Medicine, Washington, DC 20059, USA.ORCID 0000-0001-9342-6243
Rumaisa RashidDepartment of Medicine and Cancer Center, Howard University College of Medicine, Washington, DC 20059, USA.
Sabtain SaroyaDepartment of Medicine and Cancer Center, Howard University College of Medicine, Washington, DC 20059, USA.
Mrinalini DeverapalliDepartment of Medicine and Cancer Center, Howard University College of Medicine, Washington, DC 20059, USA.
Hassan BrimDepartment of Medicine and Cancer Center, Howard University College of Medicine, Washington, DC 20059, USA.
Hassan AshktorabDepartment of Medicine and Cancer Center, Howard University College of Medicine, Washington, DC 20059, USA.ORCID 0000-0002-4048-4666

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory illness of the gastrointestinal tract (GI), characterized by recurrent episodes of inflammation and tissue destruction. It affects an increasing number of individuals worldwide who suffer from Crohn's disease (CD) or ulcerative colitis (UC). Despite substantial advances in understanding the underlying causes of IBD, the available treatments remain restricted and are sometimes accompanied by severe consequences. Consequently, there is an urgent need to study alternate therapeutic options. This review assesses the present drugs, identifies their limitations, and proposes the use of saffron, a natural plant with great therapeutic potential based on preclinical and clinical investigations. Saffron has gained attention for its potential therapeutic benefits in treating various ailments due to its established bioactive compounds possessing antioxidant and anti-inflammatory properties. This review covers how saffron impacts the levels of calprotectin, an inflammatory marker, for various inflammatory responses in multiple diseases including IBD. Data from clinical trials were assessed to determine the efficacy and safety of using saffron to counter inflammation in multiple diseases. Studies have shown that saffron may protect against inflammatory bowel disease (IBD) through several mechanisms by inhibiting pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), reducing oxidative stress through antioxidant effects, enhancing mucosal barrier function by upregulating tight junction proteins, and modulating the gut microbiota composition to promote beneficial bacteria while suppressing pathogenic ones; these combined actions contribute to its therapeutic potential in managing and alleviating the symptoms of IBD. This will enable future research endeavors and expedite the translation of saffron-based interventions into clinical practice as a valuable adjunctive therapy or a potential alternative to conventional treatments, thereby enhancing the quality of life for individuals suffering from inflammatory diseases including IBD.

Indexed as

Anti-Inflammatory AgentsCrocusInflammatory Bowel DiseasesAnimalsAntioxidantsCrohn DiseaseCytokinesGastrointestinal MicrobiomeHumansOxidative StressPhytotherapyPlant ExtractsAnti-Inflammatory AgentsAntioxidantsCytokinesPlant ExtractscalprotectinCDIBDsaffronUC

Identifiers

PMID39064796
PMCPMC11280066

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.